Equity · Healthcare
AARD
NASDAQAardvark Therapeutics (AARD)
The line runs 6.87 USD on 24 August through 0.9279 USD on 20 November, on a scale from 0 to 8. Days the market did not trade hold the previous close, flat.
- Market cap
- 20.3M USD
- Revenue, year to Dec 2025
- 0 USD
- EPS, diluted, year to Dec 2025
- −2.93 USD
- Avg volume
- 25.9K
as of Nov 20, 2026
Have Aardvark Therapeutics (AARD) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Aardvark Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 11 Dec 2025.
Form 4, 90 days to 22 Nov 2026, newest reported trade 11 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Sep 2026 | Sun NelsonSee Remarks | Sell | 62,000 | 321K USD |
| 10 Sep 2026 | Sun NelsonSee Remarks | Sell | 14,754 | 74K USD |
| Sold | 2 open-market sales | 76,754 | $395K |
Which funds hold Aardvark Therapeutics (AARD)?
7 of the 45 institutional funds we track reported a Aardvark Therapeutics position for the quarter ended 30 Sep 2026 — a combined 7.8M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Held (±25%) | 975,028 | 5.1M USD | −24.0% |
| Marshall Wace | Added | 132,204 | 697K USD | +593.0% |
| Two Sigma Investments | Held (±25%) | 129,577 | 683K USD | +19.6% |
| AQR Capital Management | Trimmed | 114,053 | 601K USD | −76.3% |
| Millennium Management | Held (±25%) | 62,454 | 329K USD | −10.7% |
| D. E. Shaw & Co. | New position | 40,558 | 214K USD | |
| Point72 Asset Management | Added | 35,456 | 187K USD | +55.0% |
What has been filed or recorded for Aardvark Therapeutics (AARD)?
The filings we hold for Aardvark Therapeutics, newest first: 8 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 176,079 shares | 254K USD notional · 0.804% of shares out |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 302,948 shares | 457K USD notional · 1.384% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 507,252 shares | 659K USD notional · 2.317% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 501,028 shares | 541K USD notional · 2.289% of shares out |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 306,616 shares | 426K USD notional · 1.401% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 17,353 shares | 69K USD notional · 0.079% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 94 shares | 415 USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 198 shares | 982 USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.88 USD | |
| 30 Sep 2026 | Financials | Total assets | 64.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 57.6M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.66 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.99 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.93 USD | |
| 31 Dec 2025 | Financials | Revenue | 0 USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −57.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.93 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.75 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.66 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.71 USD | |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS −5.15 USD |
What do people ask about Aardvark Therapeutics (AARD)?
What did Aardvark Therapeutics shares close at?0.9279
Aardvark Therapeutics closed at 0.9279 USD on 20 Nov 2026, down 8.58% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Aardvark Therapeutics’ market cap?20.3M
Aardvark Therapeutics is worth 20.3M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Aardvark Therapeutics’ revenue?0
Aardvark Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Aardvark Therapeutics insiders bought or sold shares recently?2 sales
In the 90 days to 22 Nov 2026, Aardvark Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 11 Dec 2025. See Insiders
Which funds own Aardvark Therapeutics?7 of 45
7 of the 45 funds we track reported a Aardvark Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Marshall Wace and Two Sigma Investments. See Funds
When did Aardvark Therapeutics last report earnings?−0.88
Aardvark Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.88 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words